Canopy Growth (CGC) Non-Current Deferred Tax Liability (2017 - 2023)
Canopy Growth's (CGC) quarterly Non-Current Deferred Tax Liability came in at $893343.0 in Q2 2023, down 92.23% year-on-year from $11.5 million in Q2 2022, and up 238.3% quarter-over-quarter from $264071.6 in Q1 2023.
Canopy Growth (CGC) Non-Current Deferred Tax Liability (2017 - 2023) Analysis & Trends
Canopy Growth has disclosed Non-Current Deferred Tax Liability across 7 years of filings, most recently posting $893343.0 for Q2 2023.
- Non-Current Deferred Tax Liability for Q2 2023 came in at $893343.0, down 92.23% year-over-year; the trailing twelve-month figure through Jun 2023 was $893343.0 (down 92.23% YoY), and the FY2023 annual result was $264071.6, down 97.91% from the prior year.
- Non-Current Deferred Tax Liability came in at $893343.0 for Q2 2023 at Canopy Growth, up from $264071.6 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $79.0 million in Q1 2019 to a low of $264071.6 in Q1 2023.
- The 5-year median for Non-Current Deferred Tax Liability is $17.8 million (2020), against an average of $21.0 million.
- Across the five-year window, Non-Current Deferred Tax Liability jumped 197.79% in 2019 and sank 97.91% in 2023, its largest moves.
- Canopy Growth's Non-Current Deferred Tax Liability stood at $79.0 million in 2019, then sank by 77.43% to $17.8 million in 2020, then advanced by 21.73% to $21.7 million in 2021, then slumped by 69.5% to $6.6 million in 2022, then tumbled by 86.51% to $893343.0 in 2023.
- The last three Non-Current Deferred Tax Liability figures came in at $893343.0 (Q2 2023), $264071.6 (Q1 2023), and $6.6 million (Q4 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 893,342.96 |
| Jun 30, 2023 | 893,342.96 |
| Mar 31, 2023 | 264,071.60 |
| Mar 31, 2023 | 264,071.60 |
| Dec 31, 2022 | 6.62 Mn |
| Dec 31, 2022 | 6.62 Mn |
| Sep 30, 2022 | 7.48 Mn |
| Sep 30, 2022 | 7.48 Mn |
| Jun 30, 2022 | 11.50 Mn |
| Jun 30, 2022 | 11.50 Mn |
| Mar 31, 2022 | 12.62 Mn |
| Mar 31, 2022 | 12.62 Mn |
| Dec 31, 2021 | 21.71 Mn |
| Dec 31, 2021 | 21.71 Mn |
| Sep 30, 2021 | 20.23 Mn |
| Sep 30, 2021 | 20.23 Mn |
| Jun 30, 2021 | 21.62 Mn |
| Jun 30, 2021 | 21.62 Mn |
| Mar 31, 2021 | 16.89 Mn |
| Mar 31, 2021 | 16.89 Mn |